The lupus treatment landscape could soon welcome an entrant if a first-in-class anti-interferon monoclonal antibody (mAb) continues to hit clinical-trial targets. AstraZeneca and its biologics R&D branch, MedImmune, are developing anifrolumab, an investigational monoclonal antibody that blocks type 1 interferons to treat moderate to severe systemic lupus erythematosus (SLE).
{iframe}http://www.mmm-online.com/pipeline/astrazeneca-azn-lupus-bms-autoimmune-rd/article/652541/{/iframe}